13 April 2021
MTPConnect is pleased to bring you our April seminar series webinar ‘Collaboration and Skills Summit: Partnering for Success - How to maximise virtual partnering meetings!’ on 29 April 1:00pm-3:00pm AEST.
With COVID-19 limiting travel to major international conferences, and events like the BIO Convention and The MedTech Conference moving online, partnering opportunities are now more frequently explored through virtual meetings.
Join us for this seminar to explore how to partner effectively at virtual conferences when seeking
new strategic partnerships for funding or collaboration.
This seminar will focus on:
- Effective ways to participate in partnering meetings with other companies
- Setting up strategies for one on one virtual meetings
- Preparing your presentation – storytelling, interactions and presence
- Know your targets, do your research
- Tips to building trust and long-term business-to-business relationships
This will be a facilitated session hosted by MTPConnect’s Managing Director & CEO Dr Dan Grant and you will hear practical advice and case studies for successful partnering from industry experts in the MTP sector - those acquiring novel medtech and pharmaceutical products (big pharma and investors) to those developing them (startups/SMEs).
Johnson & Johnson Innovation seeks to positively impact human health through innovation by creating healthcare solutions that improve peoples’ lives around the world. Kathy Connell is the Senior Director of New Ventures, Australia and New Zealand (ANZ) for Johnson & Johnson Innovation, West North America, ANZ responsible for implementing the Johnson & Johnson external partnerships and growth strategy across ANZ. As the technology scout for the pharmaceutical, medical device and consumer health businesses, Kathy is passionate about encouraging and building global collaborations to deliver new and disruptive healthcare solutions for people everywhere. Kathy will be sharing her experiences as a buyer.
Brandon Capital Partners is Australasia’s leading life science venture capital investor, based in Melbourne. Helga Mikkelson is the Investment Analyst and assists with the management of the Medical Research Commercialisation Fund (MRCF), working with scientists, clinicians and entrepreneurs from company formation and seed investment through to expansion capital, supporting life science companies from proof-of-concept through to commercialisation.
SpeeDx Pty Ltd (SDx) is a privately-owned, Australian molecular diagnostics company that develop world-leading in-vitro-diagnostic (IVD) tests for infectious diseases and AMR using their proprietary PlexPCR™ and PlexPrim™ technologies. Colin Denver is the CEO of SpeeDx and is an experienced Business Development professional with over 20 years’ experience in the Life Science and Diagnostic fields. Following successful regional roles with Meridian Bioscience and Bioline, Colin has led SpeeDx in their commercial expansion across Australia, Europe and the USA. SpeeDx was awarded funding in MTPConnect’s Biomedical Translation Bridge program to commercialise its ResistancePlus® MABSC/MAC test and to create a rapid test for risk-based management of COVID-19, influenza, and other severe respiratory disease.
Dimerix Bioscience Limited is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dr Nina Webster is the Managing Director & CEO of Dimerix Limited and has almost thirty years of experience in the pharmaceutical industry, with leadership roles in investor relations, business development, and prosecution of intellectual property matters, as well as leading the strategic, scientific and operational aspects of product development. Dimerix was awarded funding in MTPConnect’s Biomedical Translation Bridge program for development of its proprietary product DMX-200 for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. The company is also developing DMX-200 for two different kidney disease, Diabetic Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS).
A Q&A session will also give participants the chance to submit questions.
We hope you can join us. Register today.